7 known interactions • 0 major • 4 moderate • 3 minor
Always disclose all medications to your healthcare providers — prescription medicines, OTC medications, vitamins, and herbal supplements. This list may not include every possible interaction. Use our Medicine Interaction Checker to screen your complete medication list.
Potentially life-threatening or causing permanent damage. Avoid combination.
May worsen condition or require dose adjustment. Monitor closely.
Usually limited clinical effect. Manage with routine monitoring.
Photodynamic therapy (verteporfin)
Concurrent or closely timed use of verteporfin photodynamic therapy with intravitreal aflibercept may increase the risk of intraocular inflammation. Clinical monitoring is recommended if combination treatment is used.
Other anti-VEGF agents (bevacizumab, ranibizumab, brolucizumab)
Combining anti-VEGF agents is not standard practice. Concurrent use may amplify systemic VEGF suppression, theoretically increasing cardiovascular risk. Sequential use within the same eye within short intervals may heighten inflammation risk.
Corticosteroids (intravitreal, e.g., triamcinolone, dexamethasone implant)
Combination intravitreal corticosteroid and anti-VEGF therapy is used in clinical practice for resistant DME. This combination increases the risk of elevated intraocular pressure and cataract formation and requires close monitoring.
Immunosuppressants (systemic)
Patients receiving systemic immunosuppressive therapy may have altered wound healing and a potentially increased risk of ocular infection following intravitreal injection. The risk-benefit profile should be assessed individually.
NSAIDs (topical ophthalmic, e.g., ketorolac)
Topical NSAIDs used peri-injection for pain management or inflammation suppression have a low interaction profile with aflibercept but may slightly alter corneal healing and increase epithelial fragility with prolonged use.
Anticoagulants (warfarin, apixaban, rivaroxaban)
Patients on systemic anticoagulants may experience increased conjunctival or subconjunctival hemorrhage following intravitreal injection. Systemic anticoagulation does not generally require interruption but should be documented prior to injection.
Antihypertensive agents
Although systemic absorption of intravitreal aflibercept is low, VEGF inhibition may transiently affect blood pressure regulation. Patients on antihypertensives should have blood pressure monitored periodically, particularly those with multiple cardiovascular risk factors.
Always ask your pharmacist about potential interactions with food, alcohol, and supplements specific to Aflibercept. Some medicines have significant interactions with grapefruit juice, high-fat meals, dairy products, or vitamin K-rich foods.